As Insurers Drop Obesity Drug Coverage, Access Worsens For Those Most In Need

At least 12% of adults in the U.S. have been prescribed a glucagon‐like peptide‐1 drug for one or multiple indications, but 54% of users report affordability challenges.

Continue Reading


News Source: www.forbes.com

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *